ArticleNPJ Parkinson's disease2025
Elevated plasma levels of alpha-synuclein are dispensable for Parkinson's disease pathology.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Brain-first and body-first subtypes of Lewy body disease.Nature reviews. Neurology · 2026Review
- A Systematic Comparison of Alpha-Synuclein Seed Amplification Assays for Increasing Reproducibility.Annals of clinical and translational neurology · 2026Review
- von Willebrand Factor fibers formed at pathological high shear provide a scaffold for α-synuclein binding and aggregation.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Although α-synuclein levels are elevated in the blood plasma of Parkinson's disease (PD) patients, it remains unclear whether blood-derived α-synuclein directly contributes to PD. To investigate this, we developed a novel mouse model in which human α-synuclein levels are increased in the blood. Despite a significant increase in α-synuclein in the blood, no noticeable behavioral abnormalities were observed in aged mice. Additionally, we did not observe plasma α-synuclein aggregation in the blood or entry of human α-synuclein into the brain. These results suggest that elevated blood levels of α-synuclein may not be sufficient to induce PD progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.